QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

$53.38
+2.43 (+4.77%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$50.39
$53.70
50-Day Range
$41.13
$53.38
52-Week Range
$37.59
$79.50
Volume
189,682 shs
Average Volume
146,389 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.88

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
23.4% Upside
$65.88 Price Target
Short Interest
Healthy
4.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.80mentions of Enanta Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.05) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

175th out of 1,055 stocks

Pharmaceutical Preparations Industry

81st out of 518 stocks


ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $49.00
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Update
SVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Earnings Outlook For Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. (ENTA)
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
11/21/2022
Today
1/31/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.88
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-121,750,000.00
Net Margins
-141.31%
Pretax Margin
-141.82%

Debt

Sales & Book Value

Annual Sales
$86.16 million
Book Value
$15.51 per share

Miscellaneous

Free Float
18,233,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
0.48

Key Executives

  • Jay R. LulyJay R. Luly
    President, Chief Executive Officer & Director
  • Paul J. MellettPaul J. Mellett
    CFO & Senior VP-Finance & Administration
  • Yat Sun Or
    CSO, Senior Vice President-Research & Development
  • Scott T. Rottinghaus
    Chief Medical Officer & Senior Vice President
  • Nathaniel S. Gardiner
    Secretary, Senior Vice President & General Counsel













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2023?

7 Wall Street analysts have issued 12 month target prices for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they anticipate the company's share price to reach $65.88 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2023?

Enanta Pharmaceuticals' stock was trading at $46.52 at the start of the year. Since then, ENTA stock has increased by 12.3% and is now trading at $52.24.
View the best growth stocks for 2023 here
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Monday, November, 21st. The biotechnology company reported ($1.27) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.10. The biotechnology company had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative trailing twelve-month return on equity of 34.73%. The company's revenue was down 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.22) earnings per share.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.25%), Hennion & Walsh Asset Management Inc. (0.15%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%), Inspire Investing LLC (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $52.24.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.09 billion and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 1/31/2023 by MarketBeat.com Staff